Influenza A virus subtype H3N2 (also H3N2) is a subtype of viruses that cause influenza (flu). H3N2 viruses can infect birds and mammals. In birds, humans, and pigs, the virus has mutated into many strains. H3N2 is increasingly abundant in seasonal influenza, which kills an estimated 36,000 people in the United States each year.
Combining genetic and experimental data into models about the influenza virus can help predict more accurately which strains will be most common during the next winter, says a study published recently in eLife.
A recent study by the US researchers highlights the value of the human organ chip technology as a more robust and physiologically relevant platform for rapid drug repurposing, and suggest that amodiaquine may be used to prevent the infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Penn Medicine researchers have found that middle-aged individuals -- those born in the late 1960s and the 1970s -- may be in a perpetual state of H3N2 influenza virus susceptibility because their antibodies bind to H3N2 viruses but fail to prevent infections, according to a new study led by Scott Hensley, PhD, an associate professor of Microbiology at the Perelman School of Medicine at the University of Pennsylvania.
Viruses like the influenza virus and even the novel coronavirus are capable of spreading from person to person via airborne droplets as well as dust, fibers, and other surfaces. Now, a new study provides evidence of airborne virus transport on microscopic particles called “aerosolized fomites.”
In a novel proof of concept study, published on the bioRxiv preprint server, U.S. researchers used attenuated influenza viral particles that express severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain to induce neutralizing antibodies in mice – unveiling another viable vaccine candidate for preventing coronavirus disease (COVID-19).
Oxford Nanopore today announces an agreement with the UK’s Department of Health and Social Care, to roll out its novel LamPORE test.
Strains of a common subtype of influenza virus, H3N2, have almost universally acquired a mutation that effectively blocks antibodies from binding to a key viral protein, according to a study from researchers at Johns Hopkins Bloomberg School of Public Health.
Early infections of influenza A can help predict how the virus will affect people across different ages in the future and could impact the effectiveness of flu vaccines, says a new study published today in eLife.
Some common strains of influenza have the potential to mutate to evade broad-acting antibodies that could be elicited by a universal flu vaccine, according to a study led by scientists at Scripps Research.
The COVID-19 pandemic caused by the severe acute respiratory syndrome -coronavirus 2 (SARS-CoV-2) has spread to most of the world, causing millions of cases and hundreds of thousands of deaths. A new study published on the preprint server bioRxiv* shows that a protease inhibitor drug already approved by the Food and Drug Administration (FDA) could inhibit viral entry.
Researchers at Shanghai Public Health Clinical Center have made important discoveries about the immune response among patients who have recovered from mild COVID-19 disease that could help to inform prevention and treatment methods, as well as improve the efficacy of community testing.
Of the seven coronaviruses known to infect people, four cause common respiratory infections that are sharply seasonal and appear to transmit similarly to influenza, according to a new study by University of Michigan School of Public Health researchers.
Influenza is a deadly virus, with about 290,000 to 650,000 deaths worldwide each year. When pandemics hit, the toll can soar: The Spanish flu of 1918 caused 40 million to 50 million deaths, the Asian flu of 1957 caused 2 million deaths, and the Hong Kong flu of 1968 caused 1 million deaths.
Were you born in an H1N1 year or an H3N2 year? The first type of influenza virus we are exposed to in early childhood dictates our ability to fight the flu for the rest of our lives, according to a new study from a team of infectious disease researchers at McMaster University and Université de Montréal.
On January 31, 2019, an 11-year old boy in Japan went to a medical clinic with a fever. The providers there diagnosed him with influenza, a strain called H3N2, and sent him home with a new medication called baloxavir.
Researchers have discovered a mutation in strains of influenza treated with a drug that makes the virus resistant to treatment.
Now, a new study published in the journal Science on October 25, 2019, reports on a set of three novel antibodies that bind to another type of viral cell surface antigen called neuraminidase (NA) that is necessary for viral replication.
A newly identified set of three antibodies could lead to better treatments and vaccines against influenza, according to a paper published this week in Science.
About 40 million people contracted the flu last year, with hundreds of thousands hospitalized and 35,400 to 61,000 deaths, including 134 children, according to the Centers for Disease Control and Prevention.
New research could bring scientists a step closer to developing an effective, universal flu vaccine.